Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2020 03:00 ET | Source: SpyBiotech

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

OXFORD, United Kingdom, Sept. 08, 2020 (GLOBE NEWSWIRE) -- SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its...